Literature DB >> 12734405

Vaccinia complement control protein: multi-functional protein and a potential wonder drug.

Purushottam Jha1, Girish J Kotwal.   

Abstract

Vaccinia virus complement control protein (VCP) was one of the first viral molecules demonstrated to have a role in blocking complement and hence in the evasion of host defense. Structurally it is very similar to the human C4b-BP and the other members of complement control protein. Functionally it is most similar to the CR1 protein. VCP blocks both major pathways of complement activation. The crystal structure of VCP was determined a little over a year ago and it is the only known structure of an intact and complete complement control protein. In addition to binding complement, VCP also binds to heparin. These two binding abilities can take place simultaneously and contribute to its many function and to its potential use in several inflammatory diseases, e.g. Alzheimer's disease (AD), CNS injury, xenotransplantation, etc. making it a truly fascinating molecule and potential drug.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734405     DOI: 10.1007/BF02970146

Source DB:  PubMed          Journal:  J Biosci        ISSN: 0250-5991            Impact factor:   2.795


  31 in total

1.  Conserved surface-exposed K/R-X-K/R motifs and net positive charge on poxvirus complement control proteins serve as putative heparin binding sites and contribute to inhibition of molecular interactions with human endothelial cells: a novel mechanism for evasion of host defense.

Authors:  S A Smith; N P Mullin; J Parkinson; S N Shchelkunov; A V Totmenin; V N Loparev; R Srisatjaluk; D N Reynolds; K L Keeling; D E Justus; P N Barlow; G J Kotwal
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

Review 2.  C4b-binding protein, a regulatory protein of complement.

Authors:  S R Barnum
Journal:  Immunol Res       Date:  1991       Impact factor: 2.829

Review 3.  Vaccinia virus immune evasion.

Authors:  G L Smith; J A Symons; A Khanna; A Vanderplasschen; A Alcamí
Journal:  Immunol Rev       Date:  1997-10       Impact factor: 12.988

4.  NMR studies of a viral protein that mimics the regulators of complement activation.

Authors:  A P Wiles; G Shaw; J Bright; A Perczel; I D Campbell; P N Barlow
Journal:  J Mol Biol       Date:  1997-09-19       Impact factor: 5.469

5.  A cluster of positively charged amino acids in the C4BP alpha-chain is crucial for C4b binding and factor I cofactor function.

Authors:  A M Blom; J Webb; B O Villoutreix; B Dahlbäck
Journal:  J Biol Chem       Date:  1999-07-02       Impact factor: 5.157

6.  Local neutrophil influx following lateral fluid-percussion brain injury in rats is associated with accumulation of complement activation fragments of the third component (C3) of the complement system.

Authors:  K L Keeling; R R Hicks; J Mahesh; B B Billings; G J Kotwal
Journal:  J Neuroimmunol       Date:  2000-06-01       Impact factor: 3.478

7.  Elucidation of the early events contributing to zymosan-induced multiple organ dysfunction syndrome using MIP-1alpha, C3 knockout, and C5-deficient mice.

Authors:  J Mahesh; J Daly; W G Cheadle; G J Kotwal
Journal:  Shock       Date:  1999-11       Impact factor: 3.454

8.  Genome sequence of a human tumorigenic poxvirus: prediction of specific host response-evasion genes.

Authors:  T G Senkevich; J J Bugert; J R Sisler; E V Koonin; G Darai; B Moss
Journal:  Science       Date:  1996-08-09       Impact factor: 47.728

9.  Characterization of C3dg binding to a recess formed between short consensus repeats 1 and 2 of complement receptor type 2 (CR2; CD21).

Authors:  W M Prodinger; M G Schwendinger; J Schoch; M Köchle; C Larcher; M P Dierich
Journal:  J Immunol       Date:  1998-11-01       Impact factor: 5.422

10.  Species specificity of ectromelia virus and vaccinia virus interferon-gamma binding proteins.

Authors:  K Mossman; C Upton; R M Buller; G McFadden
Journal:  Virology       Date:  1995-04-20       Impact factor: 3.616

View more
  9 in total

1.  A novel liposome-based therapy to reduce complement-mediated injury in revascularized tissues.

Authors:  Ledia Goga; Sathnur B Pushpakumar; Gustavo Perez-Abadia; Paul Olson; Gary Anderson; Chirag V Soni; John H Barker; Claudio Maldonado
Journal:  J Surg Res       Date:  2010-10-16       Impact factor: 2.192

2.  Identification of complement regulatory domains in vaccinia virus complement control protein.

Authors:  Jayati Mullick; John Bernet; Yogesh Panse; Sharanabasava Hallihosur; Akhilesh K Singh; Arvind Sahu
Journal:  J Virol       Date:  2005-10       Impact factor: 5.103

3.  Capturing the natural diversity of the human antibody response against vaccinia virus.

Authors:  Johan Lantto; Margit Haahr Hansen; Søren Kofoed Rasmussen; Lucilla Steinaa; Tine R Poulsen; Jackie Duggan; Mike Dennis; Irene Naylor; Linda Easterbrook; Søren Bregenholt; John Haurum; Allan Jensen
Journal:  J Virol       Date:  2010-12-08       Impact factor: 5.103

4.  Crosstalk between immune cell and oncolytic vaccinia therapy enhances tumor trafficking and antitumor effects.

Authors:  Padma Sampath; Jun Li; Weizhou Hou; Hannah Chen; David L Bartlett; Steve H Thorne
Journal:  Mol Ther       Date:  2012-12-11       Impact factor: 11.454

5.  Inhibition of complement and CD14 attenuates the Escherichia coli-induced inflammatory response in porcine whole blood.

Authors:  Ebbe Billmann Thorgersen; Anne Pharo; Karin Haverson; Anne K Axelsen; Peter Gaustad; Girish J Kotwal; Georgia Sfyroera; Tom Eirik Mollnes
Journal:  Infect Immun       Date:  2008-12-01       Impact factor: 3.441

Review 6.  Manipulating the mediator: modulation of the alternative complement pathway C3 convertase in health, disease and therapy.

Authors:  Daniel Ricklin
Journal:  Immunobiology       Date:  2012-11       Impact factor: 3.144

7.  Inhibitors of C5 complement enhance vaccinia virus oncolysis.

Authors:  D Magge; Z S Guo; M E O'Malley; L Francis; R Ravindranathan; D L Bartlett
Journal:  Cancer Gene Ther       Date:  2013-05-10       Impact factor: 5.987

Review 8.  Vaccinia virus-mediated cancer immunotherapy: cancer vaccines and oncolytics.

Authors:  Zong Sheng Guo; Binfeng Lu; Zongbi Guo; Esther Giehl; Mathilde Feist; Enyong Dai; Weilin Liu; Walter J Storkus; Yukai He; Zuqiang Liu; David L Bartlett
Journal:  J Immunother Cancer       Date:  2019-01-09       Impact factor: 13.751

9.  Complement-bound human antibodies to vaccinia virus B5 antigen protect mice from virus challenge.

Authors:  Nir Paran; Shlomo Lustig
Journal:  Expert Rev Vaccines       Date:  2010-03       Impact factor: 5.683

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.